The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy. We compared hazard ratios (HR) in 4287 and 685 participants who reported intakes of 1-7 and 48 drinks/week at baseline, respectively, with those in 4216 abstainers, adjusting for gender, age, smoking, exercise, and race. Within categories, clinical baseline characteristics, numbers randomized to losartan and atenolol, and blood pressure (BP) lowering were similar on the drug regimens. Overall BP control (o140/90 mmHg) at end of follow-up was similar in the categories. Composite end point rate was lower with 1-7 (24/1000 years; HR 0.87, Po0.05) and 48 drinks/week (26/1000 years; HR 0.80, NS) than in abstainers (27/1000 years). Myocardial infarction risk was reduced in both drinking categories (HR 0.76, Po0.05 and HR 0.29, Po0.001, respectively), while stroke risk tended to increase with 48 drinks/ week (HR 1.21, NS). Composite risk was significantly reduced with losartan compared to atenolol only in abstainers (HR 0.81 95% confidence interval, CI (0.68, 0.96), Po0.05), while benefits for stroke risk reduction were similar among participants consuming 1-7 drinks/ week (HR 0.73, Po0.05) and abstainers (HR 0.72, Po0.01). Despite different treatment benefits, alcoholtreatment interactions were nonsignificant. In conclusion, moderate alcohol consumption does not change the marked stroke risk reduction with losartan compared to atenolol in high-risk hypertensives. Alcohol reduces the risk of myocardial infarction, while the risk of stroke tends to increase with high intake.
Introduction
Prospective studies have suggested an inverse relationship between low-to-moderate alcohol consumption and the risk of coronary heart disease, but an increase in risk at higher levels of consumption. 1, 2 Although heavy alcohol consumption increases the risk of ischaemic as well as haemorrhagic stroke, moderate intake appears to reduce the risk of ischemic stroke. 3 Low-to-moderate alcohol consumption seems to have beneficial effects on some cardiovascular (CV) risk factors, 4 while heavy alcohol consumption has been shown to increase the risk of hypertension. 5 Thus, the relationship between alcohol intake and CV disease is complex, and may differ according to existing risk factors and disease history. To our knowledge, the impact of alcohol intake on CV risk has not previously been assessed specifically in high-risk hypertensive patients with left ventricular hypertrophy (LVH).
The Losartan Intervention For End point reduction in hypertension (LIFE) study was designed to test the hypothesis that antagonizing the actions of angiotensin II by the selective AT 1 -receptor antago-nist losartan would reduce CV morbidity and mortality compared to antihypertensive treatment with the beta-blocker atenolol in hypertensive patients with electrocardiographic (ECG) LVH. 6 Evaluation of the influence of alcohol consumption on CV event rates was defined as a tertiary objective of the LIFE study. 6 In order to evaluate alcohol consumption as a predictor of CV events, we performed a detailed analysis of its impact on various parameters in the study population. The main objectives of this analysis were to study (1) effects of alcohol consumption on the composite primary and individual secondary end points, (2) possible contributing factors for such effects, that is, effects of alcohol consumption on baseline risk factors (including blood pressure (BP) levels), and (3) possible differences in the effects of losartan and atenolol between alcohol consumption categories.
Materials and methods

Study design
The LIFE study was an investigator-initiated, prospective, multinational, multicentre, double-blind, double-dummy, randomized, active-controlled, parallel-group study. The primary objective was to compare the long-term effects of the angiotensin II receptor antagonist losartan with those of the betaadrenergic receptor blocker atenolol on CV morbidity and mortality (a composite of CV mortality, stroke, and myocardial infarction) in 9193 patients with essential hypertension and ECG-LVH. The rationale, objectives, design and methods, 6 baseline characteristics, 7 12-month follow-up data, 8 and primary outcome 9 have been published previously. The blinded treatment period continued until 16 September, 2001 , when at least 1040 patients had experienced a primary endpoint, defined as CV death, nonfatal clinically evident acute myocardial infarction (AMI), or nonfatal cerebral stroke. Participants then had a follow-up clinic visit or at least a vital status check within 6 weeks. All clinical data were verified from source documents. The trial protocol was approved by all concerned ethics committees and conducted in accordance with the Declaration of Helsinki. The study was overseen by an independent Data and Safety Monitoring Board. 6 All participants gave written informed consent.
Subjects
The LIFE study population consisted of subjects with essential hypertension and ECG-documented LVH. Sitting BP was recorded 24 h postdose (range 22-26 h). To be included, patients had to have a mean trough sitting diastolic BP of 95-115 mmHg and/or a mean sitting systolic BP of 160-200 mmHg after 1-2 weeks on single-blind placebo treatment.
Those with secondary hypertension, myocardial infarction, or stroke within the previous 6 months; angina pectoris requiring treatment with beta-blockers or calcium antagonists; heart failure or left ventricular ejection fraction o40%; or a disorder that, according to the treating physician's opinion, required treatment with study medication or related drugs were excluded. In the whole population, the mean age at inclusion was 66.9 years, 54% were women, and mean baseline BP was 174.4/ 97.8 mmHg.
Smoking, alcohol intake, and exercise status were assessed at baseline. Subjects who reported no alcohol intake were slightly older on average than those who consumed alcohol, and there were more men than women in the higher categories of consumption (Table 1) . Smoking was also more common with increasing alcohol consumption (Table 1 ). There was a slight tendency towards higher diastolic BP with increasing alcohol intake ( Table 2) . Baseline blood hemoglobin and serum uric acid levels also increased with higher alcohol intake. On the other hand, serum high-density lipoprotein (HDL) cholesterol level tended to be higher in alcohol consumers than in abstainers. The subjects' medical history differed between the drinking categories, with a tendency towards more coronary, cerebral, and peripheral vascular disease and type II diabetes in subjects who did not consume alcohol than in those who drank 1-7 drinks per week ( Figure 1 ). Other baseline characteristics of the population have been published previously. 7 
Clinical end points
The primary end point was a composite of CV death, stroke, and myocardial infarction. Other prespecified outcome measures were total mortality, angina pectoris or heart failure requiring hospitalization, coronary or peripheral revascularization procedures, resuscitated cardiac arrest, and new-onset diabetes mellitus. An Endpoint Classification Com- Figure 1 Medical history by alcohol consumption as prevalence of disease at baseline. CHD, coronary heart disease; CVD, cerebrovascular disease; PVD, peripheral vascular disease; AF, atrial fibrillation; CHF, congestive heart failure; DM, diabetes mellitus.
Alcohol in the LIFE study HM Reims et al mittee (ECC) consisting of two experienced clinicians, blinded to therapy, reviewed clinical records concerning all CV events reported by clinical centres to determine if they met protocol criteria for end points. Adverse experiences were monitored throughout the study.
ECG coding and LVH criteria
All ECGs were centrally assessed for signs of LVH, and were Minnesota coded at one reading centre.
The ECG core center also assessed silent and unrecognized myocardial infarctions. The product of QRS duration times Cornell voltage (with adjustment of 8 mm in women and a partition value of 42440 mm Â ms) and Sokolow-Lyon voltage 438 mm were chosen to recognize LVH. 6 
Biochemical methods
Two central laboratories measured serum and plasma concentrations of haemoglobin, creatinine, (5) 32 (5) 15 (5) 26 (7) 11-20/day 132 (3) 166 (5) 61 (9) 37 (12) 39 (11) 420/day 65 (2) 55 (2) 16 (2) 13 (4) 32 (9) Exercise, n (%) None 1119 (27) 651 (18) 109 (16) 68 (22) 73 (20) p30 min twice/week 1101 (26) 983 (27) 163 (24) 67 (21) 93 (25 
175 (14) 174 (14) 173 (15) 175 (14) 175 ( . Serum creatinine was analysed using the Jaffé reaction without deproteinizing and then quantified by a photometric method by using the same analyzer.
Statistical methods
Analyses of BP and CV end points were based on the intention-to-treat principle. All randomized patients were included in their randomized treatment group, and all available follow-up data were included from randomization to the end of the study. Participants who experienced more than one end point event were counted as having had an event in all relevant end point analyses; however, only the first event in a specific category was counted in individual analyses. The effect of alcohol consumption on cardiovascular end points was assessed by Cox regression models with adjustment for gender, age, smoking status, exercise habits, and race. An unadjusted analysis was also performed to validate the adjusted results. Treatment effects were measured by hazard ratios (HR) (relative risks) and 95% confidence intervals (CI) from the Cox regression models, using three drinking categories: nondrinkers (n ¼ 4216), participants consuming 1-7 drinks per week (n ¼ 4287), and participants consuming 48 drinks per week (n ¼ 685). Changes in BP and ECG measures of LVH were assessed with three drinking categories from baseline to the end of follow-up or at the last visit before a primary end point occurred, if one did. All tests were performed at two-sided 5% significance levels.
Role of the funding source
All study data reside in the Merck & Co., Inc database. Merck provided the study steering committee with free access to all data. The steering committee is free to interpret data and write manuscripts.
Results
Alcohol consumption, treatment regimens, and BP control
The numbers of patients randomized to the two study drugs were similar within the main drinking categories, but those who had eight drinks or more tended to use more antihypertensive drugs at the end of follow-up than the other two categories (Figure 2 ). On both regimens, systolic BP was lowered slightly more in the highest drinking category ( Figure 3) Figure 4 ). Figure 2 Study drug at end of follow-up or end point using three categories of alcohol consumption. Percents are given within each category of alcohol consumption. þ indicates therapy additional to given dose of study drug.
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Effects of alcohol consumption on end points
The primary composite end point rate was significantly lower in subjects who consumed 1-7 drinks per week compared to abstainers (Table 3 ). There was no significant effect for the subcategories, except in the group consuming 8-10 drinks per week (adjusted HR 0.69, 95% CI (0.48, 0.99), Po0.05). The protective effect of an intake of 1-7/week on the primary end point appeared to be dependent on gender, the adjusted HR being 0.77 (95% CI (0.63, 0.94), Po0.01) in women and 0.94 (95% CI (0.79, 1.11), P ¼ 0.459) in men (P ¼ 0.223 for interaction). There seemed to be a J-shaped relationship between alcohol intake and the primary end point in nonsmokers, which was disrupted in smokers (P ¼ 0.041 for interaction) ( Figure 5 ). The adjusted analysis revealed no significant effects of alcohol intake on CV mortality, although there was a strong trend (P ¼ 0.081) for a benefit in subjects who had 1-7 drinks per week (Table 3 ). There was a weak trend towards lower stroke risk in subjects who had 1-7 drinks per week and a trend for increased risk with higher intake. Myocardial infarction was less common among subjects who had 1-7 or 48 drinks per week than in nondrinkers, and the benefit was significant also for the subdivided categories ( Figure 6 ).
Treatment effect by alcohol consumption
In both treatment groups, end point rates were higher in abstainers than in participants consuming 1-7 drinks per week, except for identical rates of myocardial infarction in losartan-treated patients (Table 4) . Among nondrinkers, the adjusted reduction in the primary end point rate in losartan-treated patients compared to atenolol treatment was 19.2%, (95% CI (4.1, 31.9), P ¼ 0.015), while there was a weak trend (7% risk reduction) in favour of losartan treatment among subjects consuming 1-7 drinks per week, and a stronger trend (32.1% risk reduction) in those consuming 48 drinks per week ( Figure 7 ). The hazard ratios were only slightly different in the unadjusted analysis (Table 4 ). The adjusted risk reduction for stroke in subjects assigned to losartan compared to atenolol was similar in nondrinkers (28.4%, 95% CI (8.2, 44.2), P ¼ 0.009) and subjects consuming 1-7 drinks per week (26.6%, 95% CI (5.1, 43.3), P ¼ 0.018), but did not reach statistical significance in the high drinking category (Figure 7 ). There were no significant differences between the drug regimens in the risk of myocardial infarction or CV death, despite a trend in favour of atenolol (P ¼ 0.157) for myocardial infarction in those consuming 1-7 drinks per week. The results were Alcohol in the LIFE study HM Reims et al similar when race was excluded from the adjusted analyses (data not shown). The alcohol-treatment interactions from adjusted models were not significant (P ¼ 0.314 for the composite end point, P ¼ 0.668 for CV death, P ¼ 0.908 for stroke, and P ¼ 0.225 for myocardial infarction).
Discussion
The present study showed that hypertensive patients with LVH with a low-moderate consumption of alcohol (1-7 drinks/week), as well as nondrinkers, had a marked benefit with regards to stroke prevention from treatment with losartan compared to atenolol. The results suggest that low-moderate consumers benefit less than nondrinkers from losartan compared to atenolol with regards to composite end point risk reduction. However, none of the alcohol-treatment interactions were statistically significant. Even in this high-risk population, alcohol intake reduced the overall risk of myocardial infarction in a dose-dependent manner, and low-moderate intake reduced the risk of the primary composite end point. On the other hand, the adjusted risk of stroke tended to increase with high alcohol intake.
Losartan reduced the risk of stroke by 28.4 and 26.6% compared to atenolol in nondrinkers and participants with a weekly consumption of 1-7 drinks, respectively. Thus, even with less than half of the LIFE population in each of these two subgroups, there were significant benefits comparable to that in the entire LIFE population (26%), 9 while the subgroup consuming 48 drinks weekly was too small to show a significant treatment benefit. The subgroup with a weekly consumption of 1-7 drinks differed from the abstainers by showing no significant difference between the drug regimens for the primary composite end point. This contrast was largely due to the trend favouring atenolol for prevention of myocardial infarction in this category. The opposite trend in the high category of alcohol intake may be a chance finding, in view of the very large CI. Alternatively, as will be discussed, it may be explained by a particular benefit of angiotensin II antagonism in this group. Overall, the apparent effect of alcohol intake on CV disease in the present analysis parallels findings from previous studies, with an inverse relation between moderate alcohol intake and the risk of coronary heart disease, 10 and a tendency towards increased stroke risk with high intake. 3 The beneficial effect of low-moderate intake on atherosclerotic disease was apparent already from the medical history of the study participants. HDL cholesterol levels tended to increase with increasing alcohol intake, but although alcohol intake is associated with higher HDL levels, the protective effect of alcohol intake on the risk of ischaemic heart disease is strongly dependent on low-density lipoprotein (LDL) cholesterol, 11 which was not measured in the present study. The incidence of myocardial infarction was reduced with increasing alcohol intake, even when adjusted for smoking. However, the protective effect for the composite end point was absent when smokers were viewed separately. Although the prevalence of smoking was relatively low in the present study, 46.7% of men were previous smokers, while only one-third had never smoked. 7 Among women, on the other hand, twothirds have never smoked. Therefore, men had a much greater total exposure to tobacco smoke than women. But even after the adjustment for smoking, the benefit of alcohol for the composite end point was not significant in men. This is somewhat surprising, as a larger range of alcohol intake appears to be protective, at least of coronary heart disease, in men than in women. 2 Recent heavy alcohol consumption has been found to significantly increase the risk of cardioembolic stroke, even after adjustment for hypertension, smoking, hyperlipidaemia, and diabetes. 12 Nevertheless, light-to-moderate alcohol consumption has been shown to reduce the overall risk of stroke and the risk of ischaemic stroke in men. 13 Even in male smokers, light alcohol consumption may reduce the risk of cerebral infarction and haemorrhage, while heavy drinking increases the risk of all stroke Alcohol in the LIFE study HM Reims et al subtypes. 14 The beneficial effect of alcohol was attributed partly to increased HDL concentrations, and the harmful effect to increased BP. 14 In a prospective study, it was shown that among men with an initially low consumption, the risk of CV disease was reduced in those who moderately increased their consumption compared to those who maintained a low consumption. 15 While alcohol may also act protectively by decreasing platelet aggregation, lowering fibrinogen levels, interacting with aspirin in prolonging bleeding time, and increasing release of plasminogen activator, 16 these antithrombotic effects may conversely increase the risk of haemorrhagic stroke. 3 Alcohol may also cause cardiac arrhythmias and cardiomyopathy, in addition to hypertension, 1 and thereby further increase the CV risk with high consumption.
Endothelial dysfunction may play a role in the progression of coronary atherosclerosis. 17 The renin-angiotensin system, through the actions of angiotensin II, is likely to be involved by enhancement of endothelial dysfunction, vascular LDL oxidation, adhesion molecule expression, and upregulation of cytokine expression. 18 Losartan has been shown to correct human small-artery structural changes and normalize endothelial function, while atenolol had no such effects despite similar lowering of BP during treatment of hypertension. 19 In patients with atherosclerosis, losartan improves endothelium-dependent epicardial coronary vasomotion. 20 Accordingly, this drug prevents angiotensin II-induced superoxide production, inhibition of nitric oxide (NO) production, and inhibition of endothelium-dependent NO-mediated dilation in coronary arterioles. 21 Losartan apparently also has anti-inflammatory properties by inhibition of the production and release of inflammatory mediators. 22, 23 Animal studies have suggested favourable effects of low-dose alcohol exposure on endothelial function, but induction of endothelial dysfunction with higher doses. 24 Studies of the effects of alcohol on endothelial function in humans are limited, and have not established any beneficial or harmful effects of direct relevance to effects on CV outcomes. 22 However, recent studies have suggested beneficial effects of long-term moderate consumption 25 as well as acute intake 26 of alcohol on endothelial function. This is, however, probably antagonized by the increasing prevalence of cigarette smoking with increasing alcohol intake, because smoking is dosedependently associated with endothelial dysfunction, 27 facilitating inflammation, thrombosis, vasoconstriction, and atherosclerosis. 28 In addition, smoking is dose-dependently associated with higher serum concentrations of cholesterol, triglycerides, very-lowdensity lipoprotein cholesterol and LDL cholesterol, and lower HDL. 29 This probably explains the disruption of the J-shaped relationship between alcohol intake and the primary end point in smokers.
Although alcohol intake is directly associated with hypertension, 1 there were essentially no differences in BP at baseline or in BP reduction between categories of alcohol intake. The effect of alcohol intake on the risk of developing hypertension has been shown to be dose-dependent, starting at lowto-moderate levels. 30 However, while high levels of consumption have been shown to independently increase the risk of hypertension, low-moderate consumption was associated with an increase in BP in black, but not in white men. 5 Thus, because the vast majority of participants in the LIFE study were white men, our conclusion may be restricted to these. The mechanisms of alcohol-induced hypertension have remained unclear, 31 but hypotheses include involvement of the renin-angiotensin system. 4 Thus, alcohol intoxication and hangover have been reported to increase plasma renin activity, possibly due to dehydration. 32 An acute increase in renin activity was later confirmed with more moderate alcohol ingestion, and suggested to be secondary to alcohol-induced changes in fluid and electrolyte balance and BP, but not sympathetic activation. 33 With this in mind, it is interesting to note that losartan decreased LVH by ECG criteria most markedly in patients with high alcohol intake ( Figure 4 ). However, this trend was present among atenolol-treated patients as well. In this respect, one also has to remember that beta-adrenergic receptor blockers inhibit renin release 34 and suppress plasma angiotensin II levels. 35 Nevertheless, there seems to be a trend favouring losartan in preventing composite end points, CV death, and myocardial infarction in the subgroup of highest alcohol intake ( Figure 7 ). Moderate alcohol consumption may also reduce the risk of type II diabetes, 36, 37 as suggested by the somewhat lower diabetes prevalence in moderate drinkers in the present study. We did not adjust the results for diabetes at baseline, but the risk reduction for coronary heart disease with low-moderate intake appears at least as large in diabetic men as that in men without diabetes. 38 In conclusion, the angiotensin II receptor antagonist losartan markedly reduces the risk of stroke compared to atenolol in hypertensive patients with LVH with a low-moderate consumption of alcohol, as well as in abstainers. Although the risk reduction with losartan for the composite end point of CV death, stroke, and myocardial infarction could not be verified in moderate drinkers, no interaction between alcohol and treatment was observed. Even in this high-risk population, alcohol intake independently reduces the risk of myocardial infarction, while the risk of stroke tends to increase with high alcohol intake.
